NDA 021305 · Jubilant
Hicon
Sodium Iodide I-131 · Oral
Last checked: Nov 19, 2026Latest source record: Jun 11, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Jan 24, 2003
Approved uses
2
Original approval plus efficacy supplements
Registered trials
190
30 Phase 3, 19 recruiting
FAERS reports
960
900 serious, 46 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 21, 2025.
HICON ® is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. HICON ® is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid.
Mechanism: Iodide is actively transported by the sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I + ) which in turn iodinates tyrosine residues of thyroglobulin (tri or tetra-iodinated tyrosine). The beta emission of I 131 is responsible for the therapeutic effect.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 19, 2005 Supplement 3 · Efficacy LetterLabel
- Jan 24, 2003 Original approval · Type 3 - New Dosage Form LetterLabelReview
6 products under this application
- HICON · SODIUM IODIDE I-131 250-1000mCi · SOLUTION, ORAL · Prescription · TE AA
- HICON · SODIUM IODIDE I-131 1-1000mCi/ML · SOLUTION, ORAL · Discontinued
- HICON · SODIUM IODIDE I-131 1-500mCi/0.5ML · SOLUTION, ORAL · Discontinued
- SODIUM IODIDE I 131 · SODIUM IODIDE I-131 0.009-0.1mCi · CAPSULE, ORAL · Prescription
- SODIUM IODIDE I 131 · SODIUM IODIDE I-131 2-200mCi · CAPSULE, ORAL · Discontinued
- HICON · SODIUM IODIDE I-131 1-250mCi/0.25ML · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Iodide I-131" as an intervention, any sponsor and status, largest first.
- Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma PatientsPivotal-lookingStatus unknown
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT00435851 · 950 participants · Start Feb 2007
Drug: Thyrogen, thyroid hormone withdrawal, iode 131 · For: Thyroid Cancer
Sites: Villejuif, France
Fudan UniversityAcademic, hospital or other
NCT06195228 · 800 participants (planned) · Start Jan 1, 2020 · Primary completion Dec 31, 2026
Drug: dabrafenib plus trametinib with or without PD-1 antibody; entrectinib or larotrectinib with or without anti-PD-1 antibdoy and 4 more · For: Advanced Thyroid Cancer Patients Who Received Target Therapy
Sites: Fuzhou, China; Zhengzhou, China; Wuhan, China · 8 sites in all
- Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?Pivotal-lookingActive, not recruiting
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT01837745 · 776 participants · Start May 13, 2013 · Primary completion Apr 1, 2022
Drug: rhTSH stimulation; I131 · For: Low Risk Differentiated Thyroid Cancer
Sites: Villejuif, France
- Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's LymphomaCompleted
GlaxoSmithKlineGSK (GSK)
NCT00268203 · 765 participants · Start Sep 1998 · Primary completion Mar 2000
Drug: Iodine I 131 Tositumomab Therapeutic Regimen · For: Lymphoma, Non-Hodgkin
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03126916 · 750 participants (planned) · Start May 14, 2018 · Primary completion Sep 30, 2030
Drug: Busulfan; Carboplatin and 13 more · For: Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 164 sites in all
- S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's LymphomaPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00006721 · 571 participants · Start Mar 2001 · Primary completion Sep 2011
Drug: rituximab; cyclophosphamide and 3 more · For: Lymphoma
Sites: Anchorage, Alaska; Fairbanks, Alaska; Fort Smith, Arkansas · 259 sites in all
- Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid CancerPivotal-lookingStatus unknown
National Cancer Center, KoreaGovernment (non-federal)
NCT02418247 · 556 participants (planned) · Start May 2013 · Primary completion Dec 2017
Drug: I131; I123 · For: Thyroid Neoplasms
Sites: Daejun, South Korea; Goyang, South Korea; Seoul, South Korea · 5 sites in all
- A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's LymphomaPivotal-lookingStatus unknown
Corixa CorporationIndustry
NCT00078598 · 506 participants · Start Apr 2004
Drug: Rituximab or Iodine I 131 Tositumomab Therapy · For: Non-Hodgkin's Lymphoma
Sites: Atlanta, Georgia; Dayton, Ohio; Tacoma, Washington · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypothyroidism385
- endocrine ophthalmopathy36
- treatment failure26
- acute myeloid leukaemia24
- dacryostenosis acquired24
- hyperthyroidism23
- parathyroid tumour benign21
- abortion spontaneous20
- hyperparathyroidism19
- lacrimation increased19
- nausea19
- breast cancer17
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 33 |
| 2008 | 77 |
| 2009 | 56 |
| 2010 | 56 |
| 2011 | 263 |
| 2012 | 173 |
| 2013 | 82 |
| 2014 | 14 |
| 2015 | 17 |
| 2016 | 20 |
| 2017 | 6 |
| 2018 | 29 |
| 2019 | 49 |
| 2020 | 14 |
| 2021 | 50 |
| 2022 | 8 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 5 |
Recalls
1 FDA enforcement reports for this application.
Mar 11, 2016 · Class III · Terminated
Labeling: Label Error on Declared Strength
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131.
Varma VM, Beierwaltes WH, Nofal MM, et al. · JAMA 1970 · Clinical Trial, Controlled Clinical Trial
Sponsor: Jubilant · Also marketed as Sodium Iodide I 131
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.